The release states that IBN is “committed to providing the same level of service that brand partners have come to expect and that new customers can look forward to.”
IBN manufactured the Sytrinol formula for many years prior to the acquisition, including years of experience manufacturing citrus-derived polymethoxylated flavones (PMFs), a key ingredient in the blend.
Sytrinol supports healthy cholesterol and triglyceride levels, with a positive effect that studies have shown is measurable in four weeks.
Related: Omega-3 Index, Smoking Equal Predictors of CVD HPI Purchases a Stake in Bergamot Manufacturer Healthy Aging Ingredient Obtains Self-Affirmed GRAS Status
IBN intends to explore the synergistic combination of Sytrinol with the company’s clinically backed lemon flavonoid brand Eriomin, which helps address insulin resistance, pro-inflammatory cytokine production, and oxidative stress. The company is hoping to make a combo that supports both prediabetes management and cardiovascular support.“Having worked with the Sytrinol formulation for a long time, we couldn’t be happier to have this brand underneath our umbrella of citrus-derived ingredients,” said Rob Brewster, President of IBN, in the press release. “The science speaks for itself that this is among the best available ingredients for heart health, and we look forward to discovering additional ways to innovate with Sytrinol to bring it to an expanded consumer base.”
